FAQ: Oncotelic Therapeutics' Sapu003 Injectable Everolimus Clinical Trials and Bioavailability Enhancement

What is Sapu003 and what does it aim to achieve?

Sapu003 is an injectable form of Everolimus (Afinitor®) developed by Oncotelic Therapeutics that aims to significantly improve drug bioavailability from the current 10% with oral pills to 80-100% through injection, potentially enhancing treatment efficacy for breast cancer patients.

How does the Deciparticles™ technology work to improve bioavailability?

The Deciparticles™ technology creates sub-20nm nanoparticles that enable better drug delivery and absorption, allowing Everolimus to achieve dramatically higher bioavailability rates compared to traditional oral administration methods.

Who is developing Sapu003 and what is their background?

Sapu003 is being developed by Sapu Nano, part of Oncotelic Therapeutics’ GMP Bio joint venture. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company advancing a diversified pipeline spanning oncology, immunotherapy, neurodegeneration, and rare diseases.

What stage of development is Sapu003 currently in?

Sapu003 has received clearance to begin Phase 1 clinical trials, marking the initial human testing phase for this injectable formulation of Everolimus.

Why is improving Everolimus bioavailability important for cancer treatment?

Higher bioavailability means drugs may have dramatically better, faster, and more consistent efficacy for patients, potentially leading to improved treatment outcomes and more reliable therapeutic effects in breast cancer treatment.

What were the results from preclinical studies of Sapu003?

In preclinical studies, Sapu003 demonstrated the ability to raise Everolimus bioavailability from approximately 10% (as an oral pill) to anywhere from 80 to 100% when administered as an injectable formulation.

Where can investors find more information about Oncotelic Therapeutics?

The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC.

What is Oncotelic’s development strategy according to their CEO?

According to Chairman and CEO Dr. Vuong Trieu, the company focuses on de-risked, late-stage assets and accelerates their development through regulatory pathways designed for speed and efficiency, as mentioned in the BioMedWire podcast interview.